The Pharma Data

DECEMBER 14, 2020

AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.

Clinical Development 52

Clinical Development Development Clinical Supply Packaging 52

Outsourcing Pharma

AUGUST 15, 2022

Signant Health has partnered with the software company o connect its platforms for the management of clinical supply chain inventory, labels, and content.

Clinical Supply Chain 52

Clinical Supply Chain Clinical Supply Clinical Development Development 52

BioTech 365

OCTOBER 19, 2021

Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology’s Targeted Radionuclide Therapy candidate FAP-2286 BOULDER, … Continue reading (..)

Clinical Supply 40

Clinical Supply Clinical Development Development 40

The Pharma Data

SEPTEMBER 15, 2020

Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.

Clinical Supply 52

Clinical Supply Clinical Supply Chain Drugs Doctors 52

The Pharma Data

JANUARY 10, 2021

About MorphoSys MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc.,

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

OCTOBER 27, 2020

Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.

Development 40

Development Protein Manufacturing Medicine 40

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52